| . | Parameter . | Frequency (%)/median (IQR) . |
|---|---|---|
| Demographic characteristics | Total patients | 59 |
| Female | 44 (74.60) | |
| Age (in years) | 38 (30–47) | |
| Disease duration (in months) | 4 (2–12) | |
| Diabetes | 12 (20.3) | |
| Obesity (BMI ≥25) | 13 (24.1) | |
| Disease subtype (n, %) | DM | 32 (56.7) |
| PM | 5 (8.3) | |
| ASyS | 19 (31.7) | |
| IMNM | 3 (1.9) | |
| MSA (n, %) | Mi-2 | 16 (27.6) |
| Jo-1 | 12 (20.7) | |
| PL-12 | 7 (12.1) | |
| NXP-2 | 3 (5.2) | |
| MDA-5 | 4 (6.9) | |
| SRP | 1 (1.7) | |
| Negative | 12 (20.7) | |
| MAA (n, %) | PM/Scl | 1 (1.7) |
| Ro-52 | 10 (17.2) | |
| Sm RNP | 2 (5.1) | |
| Ku | 3 (5.2) | |
| Baseline enzyme levels in IU/ul (median, IQR) | CPK | 1322 (125–3695.50) |
| LDH | 648 (448.50–985.50) | |
| AST | 91(55–223) | |
| ALT | 66 (37–140) | |
| Baseline clinical disease activity measures (median, IQR) | Baseline MMT-8 (n = 59) | 60 (48–70) |
| Median (IQR) t-MRI scores of the whole cohort | Muscle oedema | 17.40 (1.85–38.88) |
| Fascial oedema | 40 (13.33–60.00) | |
| Muscle atrophy | 2.22 (0–6.66) | |
| Fatty infiltration | 0 (0–3.33) |
| . | Parameter . | Frequency (%)/median (IQR) . |
|---|---|---|
| Demographic characteristics | Total patients | 59 |
| Female | 44 (74.60) | |
| Age (in years) | 38 (30–47) | |
| Disease duration (in months) | 4 (2–12) | |
| Diabetes | 12 (20.3) | |
| Obesity (BMI ≥25) | 13 (24.1) | |
| Disease subtype (n, %) | DM | 32 (56.7) |
| PM | 5 (8.3) | |
| ASyS | 19 (31.7) | |
| IMNM | 3 (1.9) | |
| MSA (n, %) | Mi-2 | 16 (27.6) |
| Jo-1 | 12 (20.7) | |
| PL-12 | 7 (12.1) | |
| NXP-2 | 3 (5.2) | |
| MDA-5 | 4 (6.9) | |
| SRP | 1 (1.7) | |
| Negative | 12 (20.7) | |
| MAA (n, %) | PM/Scl | 1 (1.7) |
| Ro-52 | 10 (17.2) | |
| Sm RNP | 2 (5.1) | |
| Ku | 3 (5.2) | |
| Baseline enzyme levels in IU/ul (median, IQR) | CPK | 1322 (125–3695.50) |
| LDH | 648 (448.50–985.50) | |
| AST | 91(55–223) | |
| ALT | 66 (37–140) | |
| Baseline clinical disease activity measures (median, IQR) | Baseline MMT-8 (n = 59) | 60 (48–70) |
| Median (IQR) t-MRI scores of the whole cohort | Muscle oedema | 17.40 (1.85–38.88) |
| Fascial oedema | 40 (13.33–60.00) | |
| Muscle atrophy | 2.22 (0–6.66) | |
| Fatty infiltration | 0 (0–3.33) |
AST: aspartate transaminase; ASyS: antisynthetase syndrome; ALT: alanine transaminase; CPK: creatinine phosphokinase; IMNM: immune-mediated necrotizing myopathy; IQR: interquartile range; LDH: lactate dehydrogenase; MAA: myositis-associated antibodies; MMT-8: manual muscle testing-8; MSA: myositis-specific antibodies; t-MRI: thigh MRI.
| . | Parameter . | Frequency (%)/median (IQR) . |
|---|---|---|
| Demographic characteristics | Total patients | 59 |
| Female | 44 (74.60) | |
| Age (in years) | 38 (30–47) | |
| Disease duration (in months) | 4 (2–12) | |
| Diabetes | 12 (20.3) | |
| Obesity (BMI ≥25) | 13 (24.1) | |
| Disease subtype (n, %) | DM | 32 (56.7) |
| PM | 5 (8.3) | |
| ASyS | 19 (31.7) | |
| IMNM | 3 (1.9) | |
| MSA (n, %) | Mi-2 | 16 (27.6) |
| Jo-1 | 12 (20.7) | |
| PL-12 | 7 (12.1) | |
| NXP-2 | 3 (5.2) | |
| MDA-5 | 4 (6.9) | |
| SRP | 1 (1.7) | |
| Negative | 12 (20.7) | |
| MAA (n, %) | PM/Scl | 1 (1.7) |
| Ro-52 | 10 (17.2) | |
| Sm RNP | 2 (5.1) | |
| Ku | 3 (5.2) | |
| Baseline enzyme levels in IU/ul (median, IQR) | CPK | 1322 (125–3695.50) |
| LDH | 648 (448.50–985.50) | |
| AST | 91(55–223) | |
| ALT | 66 (37–140) | |
| Baseline clinical disease activity measures (median, IQR) | Baseline MMT-8 (n = 59) | 60 (48–70) |
| Median (IQR) t-MRI scores of the whole cohort | Muscle oedema | 17.40 (1.85–38.88) |
| Fascial oedema | 40 (13.33–60.00) | |
| Muscle atrophy | 2.22 (0–6.66) | |
| Fatty infiltration | 0 (0–3.33) |
| . | Parameter . | Frequency (%)/median (IQR) . |
|---|---|---|
| Demographic characteristics | Total patients | 59 |
| Female | 44 (74.60) | |
| Age (in years) | 38 (30–47) | |
| Disease duration (in months) | 4 (2–12) | |
| Diabetes | 12 (20.3) | |
| Obesity (BMI ≥25) | 13 (24.1) | |
| Disease subtype (n, %) | DM | 32 (56.7) |
| PM | 5 (8.3) | |
| ASyS | 19 (31.7) | |
| IMNM | 3 (1.9) | |
| MSA (n, %) | Mi-2 | 16 (27.6) |
| Jo-1 | 12 (20.7) | |
| PL-12 | 7 (12.1) | |
| NXP-2 | 3 (5.2) | |
| MDA-5 | 4 (6.9) | |
| SRP | 1 (1.7) | |
| Negative | 12 (20.7) | |
| MAA (n, %) | PM/Scl | 1 (1.7) |
| Ro-52 | 10 (17.2) | |
| Sm RNP | 2 (5.1) | |
| Ku | 3 (5.2) | |
| Baseline enzyme levels in IU/ul (median, IQR) | CPK | 1322 (125–3695.50) |
| LDH | 648 (448.50–985.50) | |
| AST | 91(55–223) | |
| ALT | 66 (37–140) | |
| Baseline clinical disease activity measures (median, IQR) | Baseline MMT-8 (n = 59) | 60 (48–70) |
| Median (IQR) t-MRI scores of the whole cohort | Muscle oedema | 17.40 (1.85–38.88) |
| Fascial oedema | 40 (13.33–60.00) | |
| Muscle atrophy | 2.22 (0–6.66) | |
| Fatty infiltration | 0 (0–3.33) |
AST: aspartate transaminase; ASyS: antisynthetase syndrome; ALT: alanine transaminase; CPK: creatinine phosphokinase; IMNM: immune-mediated necrotizing myopathy; IQR: interquartile range; LDH: lactate dehydrogenase; MAA: myositis-associated antibodies; MMT-8: manual muscle testing-8; MSA: myositis-specific antibodies; t-MRI: thigh MRI.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
